跳到正文
原文
MedPage Today·· 2 天前精选AI 评分75

新型肾上腺素装置在中期试验中显示出前景

Novel Epinephrine Devices Promising in Mid-Stage Trials

AI 导读

新型鼻腔干粉和舌下薄膜肾上腺素制剂在中期试验中显示出快速吸收和良好耐受性,为过敏性休克治疗提供了新的非注射选择。鼻腔干粉制剂在鼻塞患者中吸收更快,舌下薄膜制剂在5分钟内缓解症状达82.9%。

推荐理由

展示了两种新型肾上腺素给药装置在中后期试验中的有效性和安全性,为过敏性休克治疗提供了新选择。

正文

— Sublingual and dry powder intranasal formulations aim to offer options for severe allergies

November 17, 2026 • 4 min read

Novel epinephrine formulations are advancing through mid-stage trials, with promising data presented at the American College of Allergy, Asthma & Immunology (ACAAI) annual meeting.

"For years, patients' families' voice has been, 'We would love a needle-free option,'" said Jay Lieberman, MD, of the University of Tennessee Health Science Center in Memphis. "All these devices being studied, whether it's the approved nasal spray [neffy] or the nasal powders, the sublingual film that I presented data for, and there's a few others being studied. ... All of this big picture is just to give our patients options, because everything is about if you have it, if it's easier to carry, and if you're more likely to use it, that's the outcome we want."

Intranasal Powder

A double dose of a novel intranasal powder formulation of epinephrine (NS002) absorbed faster and to a greater degree than did a double dose from a standard epinephrine autoinjector (EpiPen) among patients with a stuffy nose from allergic rhinitis, simulating the severe nasal congestion that can occur with anaphylaxis.

Those were the findings from a phase II study comparing the bioavailability of the two during a nasal allergen challenge in 50 adults with allergic rhinitis. Plasma epinephrine level peaked at over 700 pg/mL at 20 minutes with the powder given twice in the same nostril compared with a still-rising level of around 500 pg/mL at that point with the EpiPen (P=0.039).

NS002 reached the T100 clinical threshold -- a surrogate for hemodynamic stabilization -- two to four times faster than the EpiPen, with a higher proportion of participants achieving that threshold in the first 5 minutes.

"The FDA wants to know, is there any effect on absorption when, in fact, you have severe nasal congestion? And so that's the purpose of the nasal allergen challenge," said presenter Michael S. Blaiss, MD, of the Medical College of Georgia at Augusta University. "And then the other thing the FDA wants is we know that maybe up to 28% of patients having an anaphylactic episode will require a second dose of epinephrine for their anaphylactic reaction. So that's why the study also looked at double doses."

NS002 raised systolic blood pressure more than EpiPen (mean increase 22 vs 6 mm Hg at 15-20 minutes) -- a desired effect, although diastolic and heart rate changes were small.

The researchers called NS002 well tolerated with transient mild symptoms but no serious or cardiovascular adverse events. While runny nose, administration site discomfort, nasal itching, and nasal congestion were common local side effects, the most common systemic adverse events were headache, nausea, shakiness, stomach discomfort, lightheadedness, and vomiting.

Blaiss said the next step is a pivotal phase III study looking at NS002 versus EpiPen and intramuscular epinephrine with similar pharmacodynamic and pharmacokinetic studies in a larger number of patients.

Sublingual Film

A novel dissolvable film for sublingual epinephrine administration showed that half of symptoms resolved within 5 minutes, climbing to 82.9% symptom resolution with 54.2% of patients asymptomatic at the 12-minute mark when maximal plasma concentration was reached, Lieberman reported at the same late-breaking oral abstract session.

The sublingual epinephrine film, dubbed dibutepinephrine, was studied in a phase II, two-part, open-label study with 110 healthy adults treated for induced oral allergy syndrome symptoms in an oral challenge model. Participants were randomized in a crossover design to a single dose of 12 mg dibutepinephrine alone or with manual intramuscular epinephrine injection without oral challenge.

Time to maximal epinephrine concentration in the blood was earlier with the sublingual film than among patients getting conventional autoinjector epinephrine or intramuscular epinephrine. The novel formulation also had higher maximal plasma epinephrine concentration and higher maximal changes in heart rate and systolic and diastolic blood pressure compared with epinephrine autoinjectors (EpiPen, AUVI-Q) and intramuscular epinephrine patients.

"The sublingual film across studies performed very similarly, whether it was in healthy subjects, whether it was in patients who were allergic and not having a reaction, or whether it was in patients having a localized allergic reaction in their mouth to kind of simulate what might happen during anaphylaxis," Lieberman said. "And the concentration curves in all the studies were very similar, reproducible. And the effects on heart rate, blood pressure, etc., are all very similar and reproducible. So it lends to the idea that this product has performed very similarly across multiple studies."

Another phase I study presented at the session reported on dibutepinephrine results when the film was placed on the top of the tongue rather than under it, as intended. Again, maximal concentration was numerically higher with the film when placed under the tongue by the patient or a physician compared with intramuscular epinephrine (391.7 and 344.5 vs 334.5 pg/mL). Time to maximal concentration was 12 minutes with the film versus 45 with intramuscular administration. But top of tongue placement of the film had a lower concentration peaking at 112.7 pg/mL at 35 minutes.

"Even if it's misplaced, such as put on the upper tongue, it doesn't get absorbed as well, but it does have some hemodynamic effects, even in the worst-case scenario. And that's very reassuring," Lieberman said.

来源:MedPage Today · medpagetoday.com